Immunohistochemical Features of an Atypical Pleomorphic Adenoma of the Salivary Gland-Overexpression of Ki-67 and p53

Kitayama, Takeyoshi; Kunimura, Toshiaki; Sugiyama, Tomoko; Omatsu, Mutsuko; Arima, Shuei; Mori, Tomoaki; Date, Hiromi; Matsuo, Kai; Ochiai, Yasuo; Mori, Kazuma; Morohoshi, Toshio

doi:10.15369/sujms.21.311

Cited by 5 publications

(5 citation statements)

References 10 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mythily and Saranya (14) found that the Ki-67 labeling index in the benign mixed tumor was 1% which is nearly similar to that of Kananceva et al result (15) . But Kaza et al (7) found a mild positive immune expression of Ki-67 in the benign mixed tumor which was 1.6%, while Kitayama et al (16) study found that the labeling index of the benign mixed tumor was 2.8%. The mean labeling index in papillary cystadenoma lymphomatosum regarding the Ki-67 immune expression was (0.16±0.13%).…”

Section: Discussionmentioning

confidence: 95%

“…Tarakji et al (26) results showed nuclear P53 were expressed strongly in 20.7% of the pleomorphic benign mixed tumors. Kitayama et al (16) found that in benign mixed tumor the P53 LI was 1.5%. The positivity of the P53 in the nuclei of tumor cells of epithelial and myoepithelial components could be caused by the accumulated mutations which may lead to the formation of carcinoma ex-PA, especially when it stays for a long period of time without any treatment.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

The differences between benign mixed tumor and papillary cystadenoma lymphomatosum in proliferative, apoptotic, and antiapoptotic activity

Khaleel¹

2019

ATMPH

View full text Add to dashboard Cite

The majority of salivary glands tumors are benign mixed tumors. The present study was aimed to evaluate the differences between benign mixed salivary glands tumor and papillary cystadenoma lymphomatous regarding the tumor cell proliferation rate, apoptotic and antiapoptotic activity. The study was performed on archived paraffinembedded salivary glands tissue of 23 benign mixed tumors and five cystadenoma lymphomatosis. Sections were stained with hematoxylin and eosin and cases with the definite diagnosis were selected for immunohistochemistry. The immunoreactivity was assessed in areas of highest positivity regarding Ki-67, P53, and bcl-2. Our results refer that benign mixed tumor and papillary cystadenoma lymphomatous showed negative immune expression for Ki-67. The P53 immune staining in benign mixed tumor appeared negative, while the papillary cystadenoma lymphomatous appeared with mild positive staining. Bcl-2 immune expression in the benign mixed tumor was moderate positive while the papillary cystadenoma lymphomatous was mild positive. We conclude that the benign mixed tumors showed significantly more Ki-67 and bcl-2 immune labeling indexes than papillary cystadenoma lymphomatous, but the P53 immune expression was less (p<0.05). This indicates that the P53 expression was not observed to be correlated with the Ki-67 or bcl-2 overexpression.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 97%

The differences between benign mixed tumor and papillary cystadenoma lymphomatosum in proliferative, apoptotic, and antiapoptotic activity

Khaleel¹

2019

ATMPH

View full text Add to dashboard Cite

show abstract

“…Moreover, [26] results showed nuclear P53 was strongly expressed in 20.7% of pleomorphic benign mixed tumor. Also, [16] found that in benign mixed tumors, P53 LI was 1.5%. The positivity of P53 in the nuclei of tumor cells of epithelial and myoepithelial components could be caused by the accumulated mutations which may lead to formation of carcinoma ex-PA, especially when it stays for a long period of time without any treatment.…”

Section: Discussionmentioning

confidence: 93%

“…On the other hand, [14] found that Ki-67 labeling index in benign mixed tumor was 1% which is nearly similar to that of [15] . In addition, [7] found a mild positive immune expression of Ki-67 in benign mixed tumor which was 1.6% while [16] found that the labeling index of benign mixed tumor was 2.8%. The mean labeling index in papillary cystadenoma lymphomatosum regarding the Ki-67 immune expression was (0.16±0.13%).…”

Section: Discussionmentioning

confidence: 97%

The Differences between Benign Mixed Tumor and Papillary Cystadenoma Lymphomatosum in Proliferative, Apoptotic and Antiapoptotic Activities

Khaleel¹

2020

ATMPH

View full text Add to dashboard Cite

Background:The majority of salivary glands tumors are benign mixed tumors. The present study was aimed to evaluate the differences between benign mixed salivary glands tumor and papillary cystadenoma lymphomatosum regarding the tumor cell proliferation rate, apoptotic and antiapoptotic activities. Methods: The study was performed on archived paraffin-embedded salivary glands tissue of 23 benign mixed tumor and five cystadenoma lymphomatosum. Sections were stained with hematoxylin and eosin and cases with definite diagnosis were selected for immunohistochemistry. The immunoreactivity was assessed in areas of highest positivity regarding Ki-67, P53 and bcl-2. Results: Benign mixed tumor and papillary cystadenoma lymphomatosum showed negative immune expression for Ki-67. The P53 immune staining in benign mixed tumor appeared negative while the papillary cystadenoma lymphomatosum appeared with a mild positive staining. The bcl-2 immune expression in benign mixed tumor was moderately positive while the papillary cystadenoma lymphomatosum was mildly positive. Conclusion:The benign mixed tumors showed significantly more Ki-67 and bcl-2 immune labeling indexes than papillary cystadenoma lymphomatosum, but the P53 immune expression was less (P<0.05). This indicated that the P53 expression was not correlated with the Ki-67 or bcl-2 over expression.

show abstract

“…High GLUT-1 immunoexpression (>25% immunostained cells) has been reported in 57% of PA [11], and the expression of GLUT-1 was found to significantly correlate with FDG uptake [5]. Low Ki-67 index has been reported for PA, in the range 0.8-6.7% [12][13][14][15][16][17][18][19]. In carcinoma expleomorphic adenoma (CXPA), defined as a carcinoma arising from a primary or recurrent benign PA, Ki-67 index was high (49.3%).…”

mentioning

confidence: 99%

Proliferation PET/CT Imaging of Salivary Gland Tumor

Minamimoto

2021

Diagnostics

View full text Add to dashboard Cite

Salivary gland tumors are rare neoplasms which vary in terms of origin and malignant potential. 2-[18F]-fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography (PET) has limited ability to differentiate between different types of salivary gland tumors because both Warthin’s tumors and pleomorphic adenomas usually show increased FDG uptake, with no statistically significant difference in standardized uptake value (SUV) compared with malignant salivary gland tumors. Here, we discuss 4′-[methyl-11C]-thiothymidine (4DST) PET, which provides cell proliferation imaging capable of demonstrating intense uptake in parotid carcinoma and Warthin’s tumor, but no uptake in parotid pleomorphic adenoma. This is the first report of the potential of proliferation PET/ computed tomography (CT) imaging for characterizing salivary gland tumors based on the molecular pathogenesis of the tumor.

show abstract

Immunohistochemical Features of an Atypical Pleomorphic Adenoma of the Salivary Gland-Overexpression of Ki-67 and p53

Cited by 5 publications

References 10 publications

The differences between benign mixed tumor and papillary cystadenoma lymphomatosum in proliferative, apoptotic, and antiapoptotic activity

The differences between benign mixed tumor and papillary cystadenoma lymphomatosum in proliferative, apoptotic, and antiapoptotic activity

The Differences between Benign Mixed Tumor and Papillary Cystadenoma Lymphomatosum in Proliferative, Apoptotic and Antiapoptotic Activities

Proliferation PET/CT Imaging of Salivary Gland Tumor

Contact Info

Product

Resources

About